Observational studyAlimentary pharmacology & therapeutics2021

Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.

Cristina Bezzio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.